

Contents

<i>Reader’s Note</i>	<i>page xi</i>
<i>Acknowledgments</i>	<i>xiii</i>
Prologue: Revolution, Transition, and Transformation	1
1 Medical Profession Sovereignty to Protect and Promote the Science and Evidence Base of US Medicine	27
A Profession Built on the Evidentiary-Science Base of Medicine	28
US Law-Policy Recognition of Clinical Medicine as the Medical Profession’s Domain	31
National Regulation for Market Safety	32
National Regulation to Require <i>Premarket</i> Proof of Safety	37
The Medical Profession’s Role as Sentinel over Clinical Use	40
National Regulation to Require <i>Premarket</i> Proof of Efficacy	41
The “US Drug Lag”	45
Deference to and Reliance on the Medical Profession	47
The Resulting Medical Profession–FDA Symbiotic Relationship	50
2 US Integration of Government, Academia, and Industry: A Catalyst for Science-Technology Revolutions	73
The Latest US Application of Triple-Threat Science R&D Methodology: Operation Warp Speed/OWS	76
OWS Implementation of Triple-Threat R&D Methodology	79
The Origin of US Science R&D Triple-Threat Methodology: WWII Necessity	85
The US Government’s Centralist Role in Science-Technology R&D	86
The Biotech Revolution	91
The Genomic Revolution	94
The US Triple-Threat Past, Present, and Personal Genome Medicine/PGM Future	98

3	Direct-to-Consumer/DTC and Direct-to-Physician/DTP Biopharma Marketing in the US	124
	US DTC and DTP Biopharma Marketing	125
	Recognition of Biopharma Marketing as Protected Commercial Speech	127
	FDA Regulation of DTC Biopharma Marketing	133
	The Impact of US Biopharma Marketing on the Practice of Medicine	136
	Early Twentieth-Century Patent Medicines Marketing Norms in a Personal Genome Medicine/PGM Era	139
4	The Evolution of Consumer Genetic Testing Services from Oncormed, Inc. to 23andMe Holding Co.	158
	Era of FDA Restraint	160
	Era of FDA Confrontation, Deliberation, and Negotiation	167
	23andMe: The Seminal Direct-to-Consumer, Genetic-Health-Risk/DTCGHR Testing Services Company	170
	Medical Profession Concerns – Then and Now	176
5	Vulnerability of the Science and Evidence Base of US Medicine	202
	Medical Science, the Public, and the Medical–Industrial Complex	207
	Today’s US Physician–Patient Relationship and the State of Physician Decision Making	214
	Stewardship of the Evidentiary-Science Base of Medicine	222
	Medical Journal Direct Financial Dependence on Industry	226
	The Risk of Industry Capture of Medical Journal Content	227
	Industry Influences on Medical Profession Education	237
	Science, Standard of Care, and the Ineffectiveness of US Practice Guidelines	241
	The Absence of Centralized, Objective, Reliable Health Technology Assessment/HTA in US Health Care	248
	The Cost and Waste Consequences of Weakening the Evidentiary-Science Base of US Medicine	251
6	A Warning Label for Direct-to-Consumer/DTC Genetics and Genomics	299
	The Complexities of Personal Genome Medical Decision-Making	303
	US Health Care System and Consumer Genetics and Genomics Market Issues	311
	Consumer Genetics and Genomics Ethical, Legal, and Social Implications	317
	Privacy and Associated Risks	318

	<i>Contents</i>	ix
	Informed Consent and Commercialization	323
	Research Findings and Participants: Whether to Share	330
7	Protecting and Promoting the Evidentiary-Science Base of Personal Genome Medicine/PGM	365
	Twentieth-Century Regulation of Patent Medicine Manufacturers to Protect Consumers and Establish the Evidentiary-Science Base of Medicine	367
	Twenty-First-Century Resurrection of Buyer Beware in DTC Genetics and Genomics	368
	Regulatory Oversight of the Personal Genome Testing Cornerstone of PGM	371
	Proposals to Enhance FDA Regulation of Personal Genome Tests	373
	Proposals to Enhance CLIA Regulation of Personal Genome Testing	383
	Centralized, Reliable, Ongoing Awareness and Clinical Assessment of US Market-Available Personal Genome Tests	385
	Phase I: A Comprehensive Registry for All Health-Related Personal Genome Tests Available on the US Market	394
	Phase II: A Clinical Data Repository Component	395
	Phase III: A Clinical Use Assessment Component	395
	Public Transparency and User-Friendly Access	396
	Existing Means to Implement the Proposed Comprehensive Registry and Clinical Use Assessment Clearinghouse	397
	Global Collaboration Consistent with the Human Genome Project/HGP, COVID-19 Responsiveness, and Other Initiatives	400
	Transition and Transformation: Personal Genome Autonomy and Responsible PGM	402
	Epilogue: The Personal Genome Future of US Medicine	435
	<i>Index</i>	447